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Background:  Neisseria  meningitidis  serogroup  B  (MnB)  is  an  important  cause  of  invasive  meningococcal
disease  (IMD).  A  MnB  vaccine  (bivalent  rLP2086,  Trumenba®)  consisting  of  2 factor  H binding  protein
variants  received  accelerated  approval  in  the  United  States  for  the  prevention  of  IMD  caused  by  MnB  in
individuals  10–25  years  of age.  This  randomized,  active-controlled,  observer-blind  study  further  assessed
the  safety  and  tolerability  of  bivalent  rLP2086.
Methods:  Eligible  subjects  ≥10 to <26  years  were  randomized  (2:1)  to  receive  bivalent  rLP2086  at  months
0,  2,  and 6, or hepatitis  A  virus  vaccine  (HAV,  Havrix®) at months  0 and  6, and  saline  at month  2.  The
primary  endpoints  were  serious  adverse  events  (SAEs)  throughout  the  study  and  medically-attended
adverse  events  (MAEs)  within  30 days  after  vaccination.  Additional  safety  assessments  included  SAEs  at
other study  intervals  and  adverse  events  (AEs)  during  the  vaccination  phase.
Results: Of  5712  subjects  randomized,  84.6%  (n =  3219)  of  bivalent  rLP2086  recipients  and  87.2% (n  =  1663)
of HAV/saline  recipients  completed  the  study.  Throughout  the  study,  SAEs  were  reported  for  1.6% and
2.5% of  bivalent  rLP2086  and HAV/saline  recipients,  respectively.  SAEs  related  to  either vaccine  were  rare.
MAEs occurred  in  7.0%  and  6.1%  of subjects  after  vaccination  1; 5.5% and 6.1%  after  vaccination  2;  and
5.3%  and 5.5%  after  vaccination  3  in  the bivalent  rLP2086  and HAV/saline  groups,  respectively.  A  greater
proportion  of  subjects  reported  AEs  during  the  vaccination  phase  after  bivalent  rLP2086  compared  with
HAV/saline  recipients;  however,  when  reactogenicity  events  were  excluded,  the proportion  between
groups  was  similar.
Conclusion: This  safety  study,  the  largest  randomized,  active-controlled  trial  evaluating  a  recombinant
MnB  vaccine,  demonstrated  that  bivalent  rLP2086  is  safe  and  tolerable  in healthy  individuals  ≥10  to  <26
years  of age.
©  2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-NDAbbreviations: AE, adverse event; fHBP, factor H binding protein; HAV, hepatitis A viru
vent;  MnB, Neisseria meningitidis serogroup B; NDCMC, newly-diagnosed chronic medic
 Clinical Trials Registration: NCT01352793.
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. Introduction
Neisseria meningitidis is a leading cause of invasive meningococ-
al disease (IMD) with peaks of incidence in children younger than
 years, and in adolescents and young adults [1,2]. N. meningitidis
aused by serogroup B (ie, capsular group B; MnB) is associated with
pproximately 75% of cases of meningococcal disease in Europe
2–4] and 20–50% of cases in the United States [5]. Mortality
ates associated with IMD  approach 20% [6–8], but many survivors
xperience sequelae such as hearing loss, seizures, and behavioral
roblems after meningococcal meningitis, and limb amputation,
hronic pain and skin scarring after meningococcal septicemia [9].
Capsular polysaccharide conjugate vaccines are effective in pre-
enting disease associated with N. meningitidis serogroups A, C, Y,
nd W-135 [10]. However, because of the homology of MnB  cap-
ular polysaccharides with polysialic acid structures present on
uman neural cells [11], MnB  polysaccharide conjugate vaccines
re not immunogenic [11]. The development of polysaccharide-
ased vaccines for this serogroup has not been possible. Alternative
pproaches have been necessary to identify meningococcal anti-
ens for development of an effective vaccine protective against
iverse MnB  strains.
The N. meningitidis virulence factor LP2086 is a human fac-
or H binding protein (fHBP) present on the surface of nearly all
nB  strains [12,13]. Two genetically and immunologically dis-
inct fHBP subfamilies (A and B) have been identiﬁed [12]. Bivalent
LP2086 (Trumenba®), is a prophylactic MnB  vaccine consisting
f equal amounts of recombinant subfamily A and B fHBP pro-
eins. The vaccine elicits serum bactericidal antibodies that kill
iverse MnB  strains [14] expressing fHBPs from either subfamily,
egardless of whether these have homologous or heterologous
equences compared with those in the vaccine [14–18]. Previous
linical studies demonstrated the safety, tolerability, and immuno-
enicity of bivalent rLP2086 in children, adolescents and young
dults [14,16–19]. Based on these data, bivalent rLP2086 received
ccelerated approval from the US Food and Drug Administration in
014 for the prevention of IMD  caused by MnB  in individuals 10–25
ears of age [20,21]. In 2015, a second MnB  vaccine, 4CMenB, which
ontains a non-lipidated form of fHBP from MnB  subfamily B, was
lso licensed in the United States for the same population [21–24].
CMenB was previously licensed in the European Union and other
egions for administration to individuals 2 months of age and older
through 17 years of age in Canada) [25–27].
This study assessed further the safety and tolerability of biva-
ent rLP2086 among adolescents and young adults aged ≥10 to <26
ears when administered at 0, 2, and 6 months. This is the largest
andomized, active-controlled study to date designed to investigate
he safety of a recombinant MnB  vaccine.
. Methods
.1. Study design
Subjects in this phase 3, randomized, active-controlled,
bserver-blind study were randomized 2:1 to receive bivalent
LP2086 at months 0, 2, and 6, or hepatitis A virus vaccine (HAV,
avrix®) at months 0 and 6, and saline at month 2. HAV was
hosen because of the well-established safety proﬁle of this vac-
ine [28]. Subjects were stratiﬁed into 10- to <19-year and 19-
o <26-year cohorts to ensure adequate representation of ado-
escents and young adults. The study was conducted at 78 sites
n Australia, Chile, Czech Republic, Denmark, Estonia, Finland,
ermany, Lithuania, Poland, Spain, Sweden, and the United States
etween November 2012 and September 2014. The ﬁnal protocol,
ny amendments, and informed consent document were reviewed34 (2016) 1465–1471
and approved by the institutional review boards and/or inde-
pendent ethics committees for each participating study site. The
study was conducted in compliance with the ethical principles
originating in or derived from the Declaration of Helsinki and in
compliance with all International Conference on Harmonisation
Good Clinical Practice Guidelines, and local regulatory require-
ments. Written informed consent was obtained from all subjects (or
their parents/legal guardians) before study enrollment and before
performance of any study-related procedures.
2.2. Study objectives
The primary objective was  to evaluate the safety of bivalent
rLP2086 compared with HAV/saline, as assessed by serious adverse
events (SAEs) throughout the study and medically-attended
adverse events (MAEs) within 30 days after each vaccination.
Secondary objectives were to evaluate the safety proﬁle of biva-
lent rLP2086 vaccine compared with HAV/saline, as measured
by adverse events (AEs), SAEs, newly-diagnosed chronic medical
conditions (NDCMCs), MAEs, immediate AEs and missed days of
school/work at various study intervals. Immunogenicity data were
not collected.
2.3. Study participants
Primary inclusion criteria were healthy males or females ≥10
to <26 years of age at enrollment available for the entire study
period. Sexually active subjects of childbearing potential had to
agree to use a highly effective method of contraception throughout
the study. Key exclusion criteria were receipt of a previous MnB  or
HAV vaccine, contraindication for HAV vaccination, scheduled to
receive ≥1 dose of human papillomavirus vaccine between visit 1
and 28 days after vaccination 2, experienced a previous anaphylac-
tic reaction to any vaccine or vaccine-related component, a history
of microbiologically-proven disease caused by N. meningitidis or N.
gonorrhea, or current pregnancy or breastfeeding.
2.4. Vaccines administered
Bivalent rLP2086 (120 g) was formulated and administered as
previously described [17]. HAV contains 720 ELISA units (EL.U.)
or 1440 EL.U. of viral antigen per 0.5-mL or 1.0-mL dose, respec-
tively. Age-speciﬁc doses of HAV were administered according
to country-speciﬁc guidelines. Placebo consisted of normal ster-
ile saline solution for injection (0.9% sodium chloride) supplied as a
0.5-mL dose. Vaccines or placebo were administered into the upper
deltoid muscle of the arm with a 25-gauge, 1-inch needle.
2.5. Safety and tolerability assessments
Safety information was collected during monthly visits/contacts
between months 0 and 7 (the vaccination phase) and approxi-
mately 6 months after the last vaccination (the follow-up phase).
The primary endpoints were the percentage of subjects with ≥1
SAE during the study period (the vaccination through follow-up
phases), and the percentage of subjects with ≥1 MAE occurring
within 30 days after each vaccination. Secondary endpoints were
the percentage of subjects with ≥1 SAE, MAE, NDCMC, AE, and
immediate AE occurring during speciﬁc analysis intervals; and the
percentage of subjects who  missed days of school or work because
of AEs. NDCMCs (as reported by the investigator) were deﬁned as
a disease or medical condition, not previously identiﬁed, that was
expected to be persistent or otherwise long-lasting in its effects.
MAEs were non-serious AEs requiring evaluation at a healthcare
facility. Immediate AEs were those that occurred within the ﬁrst
30 min  after study vaccination. Electronic diaries were not used as
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Table  1
Predeﬁned reactogenicity terms.a
Vaccination siteb pain Injection siteb pain Arthralgia Body temperature increased
Vaccination site swelling Injection site swelling Myalgia Chills
Vaccination site induration Injection site induration Fatigue Diarrhea
Vaccination site erythema Injection site erythema Malaise Headache
Vaccination site inﬂammation Injection site inﬂammation Pyrexia Vomiting
Vaccination site discomfort Injection site discomfort
Vaccination site edema Injection site edema
a Reactogenicity events were deﬁned as any adverse event with an onset within 7 days after vaccination.
b Vaccination site reactions and injection site reactions are coded separately in MedDRA and are both included to ensure that all reactogenicity events were captured.
N=5712Randomized
Bivalent rLP2086
n=3804
HAV + Saline
n=1908
n=3796 
n=3530
n=3314
n=1908
n=1806
n=1710
Vaccin aon 1
Vaccin aon 2
Vaccinaon 3
n=3280 n=1688
Vaccinaon
phase
completed
n=3219 n=1663Study
completed
Reaso ns for  withd rawal 
durin g vaccin aon 
phase (n=516):
Lost to foll ow-up,  n=231
Withd rew  consent, n=63
No longer  willing to
parcip ate in stud y, n=57
Adverse event,  n=44
Other, n=121
Reaso ns for withd rawal 
durin g vaccin aon 
phase (n=220):
Lost to foll ow-up,  n=102
Withd rew consent,  n=32
Protocol viol aon , n=23
No lon ger  willing  to
parcipate in stud y, n=22
Other, n=41
Reasons for withdrawal 
durin g foll ow-up phase  
(n=61):
Lost to follow-up, n=58
Pregnancy, n=1
Protocol viol aon , n=1
Other, n=1
Reasons for withdrawal 
durin g foll ow-up phase  
(n=25):
Lost to foll ow-up, n=23
Pregnancy, n=1
Withd rew  consent,  n=1
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he overall study purpose was to identify uncommon safety events
n a large population exposed to bivalent rLP2086. Reactogenicity
local reactions and systemic events) was therefore reported in the
ame manner as all other AEs. Reactogenicity events are those often
ssociated with vaccine administration and which occurred with an
nset within 7 days after vaccination. These events matched a list of
erms identiﬁed prior to database lock to facilitate reactogenicity-
peciﬁc analyses (Table 1). Any instance of an event matching
he list that occurred outside the 7-day period was analyzed and
resented with non-reatogenicity adverse events. The severity of
vents was determined by the investigator and was  graded as either
ild (did not interfere with the subject’s usual function), moder-
te (interfered to some extent with the subject’s usual function), or
evere (interfered signiﬁcantly with the subject’s usual function).
.6. Statistical methods
This study planned to enroll 5700 subjects with a randomiza-
ion ratio of 2:1 (bivalent rLP2086:control). Assuming all enrolled
ubjects had safety data available, the sample size would provide
pproximately 84% power to detect statistical signiﬁcance (2-sided
lpha = 5%, Fisher’s exact test) when the background SAE percent-
ge is 2.5% (HAV/saline, n = 1900) and the percentage in the active
roup is 4% (bivalent rLP2086, n = 3800).
The safety population included all subjects who  received at least
 dose of investigational product and for whom safety informationisposition.
was available. Although the study planned for subject withdrawals,
nearly all subjects received at least 1 dose of investigational prod-
uct and were included in the safety analysis. All AEs and SAEs were
categorized according to the Medical Dictionary for Regulatory
Activities (MedDRA, Version 17.0) and were summarized according
to investigational product received. Brighton Collaboration terms
[29] were not used in this study to describe AEs as these terms
were not supportive of the safety endpoint assessments. Safety
data related to primary and secondary endpoints were summarized
with the number and percentage of subjects experiencing at least
1 event and the number of events. In addition, 95% CIs were cal-
culated (based on Clopper–Pearson method) for the primary and
secondary endpoints for each group. Fisher’s exact test was  used to
compare the proportions between the bivalent rLP2086 and HAV
groups and P values were presented along with the primary and
secondary endpoints. Statistical comparisons between the groups
were descriptive and were not used for inference-making.
3. Results
3.1. Study populationOf 5712 subjects randomized (bivalent rLP2086, n = 3804;
HAV/saline, n = 1908; Fig. 1), 5704 subjects (99.9%) received at least
one vaccination (bivalent rLP2086, 99.8%; HAV/saline, 100.0%), and
4968 subjects (87.0%) completed the vaccination phase (bivalent
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Table  2
Subject demographics.
Vaccine group
Bivalent rLP2086
(N = 3796)
n (%)
HAV/saline
(N = 1908)
n (%)
Sex
Female 1959 (51.6) 995 (52.1)
Race
White 3344 (88.1) 1692 (88.7)
Black 325 (8.6) 162 (8.5)
Asian 79 (2.1) 34 (1.8)
Other 48 (1.3) 20 (1.0)
Ethnicity
Non-Hispanic/non-Latino 3198 (84.2) 1614 (84.6)
Hispanic/Latino 598 (15.8) 294 (15.4)
Country
Australia 134 (3.5) 71 (3.7)
Chile 223 (5.9) 111 (5.8)
Czech Republic 207 (5.5) 102 (5.3)
Denmark 171 (4.5) 84 (4.4)
Estonia 165 (4.3) 85 (4.5)
Finland 191 (5.0) 96 (5.0)
Germany 129 (3.4) 66 (3.5)
Lithuania 292 (7.7) 146 (7.7)
Poland 581 (15.3) 292 (15.3)
Spain 99 (2.6) 51 (2.7)
Sweden 48 (1.3) 24 (1.3)
United States 1564 (41.2) 780 (40.9)
Age at ﬁrst vaccination (year)
10 to <19 2196 (57.9) 1104 (57.9)
19–26 1600 (42.1) 804 (42.1)
Mean (SD) 17.4 (4.6) 17.4 (4.6)
Median (range) 18.0 (10, 25) 17.0 (10, 25)
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During the vaccination phase, AEs related to study vaccine wereAV, hepatitis A virus vaccine; SD, standard deviation.
LP2086, 86.2%; HAV/saline, 88.5%). During the vaccination phase,
% of subjects withdrew from study because of an AE. A total
f 4882 subjects (85.5%) completed the study (bivalent rLP2086,
4.6%; HAV/saline, 87.2%). Demographic characteristics were simi-
ar between groups (Table 2). Mean (SD) age at enrollment was  17.4
4.6) years.
.2. Serious adverse events
Serious AEs during the study period (a co-primary endpoint)
ere reported by a numerically greater proportion of HAV/saline
ecipients (2.5%) compared with bivalent rLP2086 recipients (1.6%;
able 3). The most commonly reported system organ class of
AEs was infections and infestations (bivalent rLP2086, n = 20
0.5%]; HAV/saline, n = 13 [0.7%]). The most commonly reported
AEs were appendicitis (bivalent rLP2086, n = 3; HAV/saline,
 = 4), spontaneous abortion (bivalent rLP2086, n = 2; HAV/saline,
 = 3), gastroenteritis (HAV/saline: n = 3), suicidal ideation (bivalent
LP2086, n = 3; HAV/saline, n = 1), depression (HAV/saline, n = 3),
nd asthma (bivalent rLP2086, n = 3). No other single SAE was
eported by >2 subjects in either vaccine group. Few subjects
eported SAEs considered by the study investigator to be related
o study vaccination throughout the study period (n = 2 in each
roup): neutropenia and an anaphylactic reaction in the bivalent
LP2086 group, and demyelination and spontaneous abortion in
he HAV/saline group.
The proportions of subjects reporting ≥1 SAE were similar in
he bivalent rLP2086 and HAV/saline groups within 30 days after
ach vaccination (0.2% vs 0.4% for vaccinations 1 and 2; 0.3% vs
.1% for vaccination 3), within 30 days after any vaccination (0.6%
s 0.9%), during the vaccination phase (1.2% vs 1.8%), and during
he follow-up phase (0.4% vs 0.9%).34 (2016) 1465–1471
3.3. Medically-attended adverse events
The proportions of subjects reporting ≥1 MAE  within 30
days after each vaccination (a co-primary endpoint) were simi-
lar between bivalent rLP2086 recipients and HAV/saline recipients
(7.0% vs 6.1% after vaccination 1; 5.5% vs 6.1% after vaccination 2;
and 5.3% vs 5.5% after vaccination 3) (Table 3). Most MAEs were
mild or moderate in severity.
Similar proportions of bivalent rLP2086 and HAV/saline recip-
ients reported MAEs after any vaccination (14.4% vs 14.6%,
respectively), during the vaccination phase (24.6% vs 24.5%), dur-
ing the follow-up phase (11.2% vs 11.4%), and throughout the study
(29.0% in both groups). The most commonly reported MAEs during
the vaccination phase were upper respiratory tract infection (n = 57
[1.5%]), pharyngitis (n = 57 [1.5%]), headache (n = 45 [1.2%]), and
bronchitis (n = 42 [1.1%]) in bivalent rLP2086 recipients and upper
respiratory tract infection (n = 37 [1.9%]), bronchitis (n = 24 [1.3%]),
oropharyngeal pain (n = 24 [1.3%]), and headache (n = 24 [1.3%])
in HAV/saline recipients. No notable differences were observed
between groups for types of MAEs for any study period. The most
common MAEs considered by the investigator to be related to study
vaccination were pyrexia (n = 10 [0.2%]), injection site pain (n = 8
[0.2%]), headache (n = 8 [0.2%]), and injection site swelling (n = 6
[0.2%]) in the bivalent rLP2086 group, and headache (n = 4 [0.2%])
in the HAV/saline group.
3.4. Newly-diagnosed chronic medical conditions
Similar proportions of bivalent rLP2086 and HAV/saline recip-
ients reported NDCMCs 30 days after each vaccination (0.1–0.2%
and 0.1–0.3%, respectively), 30 days after any vaccination (0.5%
in both groups), during the vaccination phase (1.0% vs 1.1%), dur-
ing the follow-up phase (0.4% vs 0.5%), and throughout the study
(1.4% vs 1.5%; Table 3). The most commonly reported NDCMCs
during the vaccination phase were myopia (n = 4 [0.1%]) and atten-
tion deﬁcit/hyperactivity disorder (n = 3 [0.8%]) in bivalent rLP2086
recipients, and type 1 diabetes mellitus, anxiety, dysthymic disor-
der, and major depression (n = 2 [0.1%] for all events) in HAV/saline
recipients. NDCMCs considered by the investigator to be related to
study vaccination were rare. In the bivalent rLP2086 group, alopecia
areata was reported by 1 subject during the vaccination phase, and
in the HAV/saline group, multiple sclerosis was reported by 1 sub-
ject in the follow-up phase. No notable differences were observed
between vaccination groups for types of NDCMCs during any anal-
ysis interval.
3.5. Adverse events
A greater proportion of bivalent rLP2086 recipients reported
AEs within 30 days after each vaccination compared with recipi-
ents of HAV/saline (15.0–31.5% vs 10.8–19.0%, respectively), within
30 days after any vaccination (43.0% vs 31.5%), and during the
vaccination phase (51.1% vs 42.5%). With reactogenicity events
excluded, 37.8% (n = 1436) and 37.3% (n = 711) of bivalent rLP2086
and HAV/saline recipients, respectively, reported ≥1 AE during
the vaccination phase (Table 4). A greater proportion of bivalent
rLP2086 recipients reported local injection site AEs compared with
HAV/saline. The most commonly reported AEs during the vaccina-
tion phase were injection site pain (19.0%, n = 722), headache (6.2%,
n = 234), and pyrexia (6.1%, n = 231) among bivalent rLP2086 recip-
ients, and injection site pain (7.8%, n = 149), headache (4.8%, n = 92),
and nasopharyngitis (4.4%, n = 83) among HAV/saline recipients.more commonly reported by bivalent rLP2086 recipients compared
with HAV/saline recipients (28.9% and 12.4%, respectively). Exclud-
ing reactogenicity events, the proportion of subjects reporting AEs
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Table  3
Subjects reporting ≥1 serious adverse event, ≥1 medically-attended adverse event, and newly-diagnosed chronic medical conditions for each analysis interval.
Na ≥1 serious adverse
event nb (%)
≥1 medically-attended
adverse event nb (%)
Newly-diagnosed chronic
medical conditions nb (%)
Bivalent
rLP2086
HAV/
saline
Bivalent
rLP2086
HAV/
saline
P-valuec Bivalent
rLP2086
HAV/
saline
P-valuec Bivalent
rLP2086
HAV/
saline
P-valuec
Within 30 days after vaccination 1 3796 1908 7 (0.2) 8 (0.4) 0.108 267 (7.0) 117 (6.1) 0.218 8 (0.2) 2 (0.1) 0.512
Within 30 days after vaccination 2 3529 1806 6 (0.2) 8 (0.4) 0.087 194 (5.5) 110 (6.1) 0.383 6 (0.2) 6 (0.3) 0.238
Within 30 days after vaccination 3 3313 1710 11 (0.3) 2 (0.1) 0.241 177 (5.3) 94 (5.5) 0.843 3 (0.1) 2 (0.1) >0.999
Within 30 days after any vaccination 3796 1908 23 (0.61) 18 (0.9) 0.183 546 (14.4) 278 (14.6) 0.873 17 (0.5) 10 (0.5) 0.686
During the vaccination phase 3796 1908 44 (1.2) 35 (1.8) 0.042 934 (24.6) 468 (24.5) 0.974 39 (1.0) 20 (1.1) >0.999
During the follow-up phase 3400 1733 15 (0.4) 15 (0.9) 0.079 382 (11.2) 198 (11.4) 0.852 15 (0.4) 9 (0.5) 0.671
Throughout the study 3796 1908 59 (1.6) 48 (2.5) 0.013 1101 (29.0) 554 (29.0) >0.999 53 (1.4) 29 (1.5) 0.724
HAV, hepatitis A virus vaccine; SD, standard deviation.
a N = number of subjects who are in safety population for the speciﬁed analysis interval. The values in this column are used as the denominators for percentages.
b n = number of subjects with at least 1 event for the speciﬁed analysis interval.
c Fisher exact test (2-sided) to compare the percentages.
Table 4
Subjects reporting ≥1 adverse event for each analysis interval.
Na Bivalent rLP2086 nb % Na HAV/saline nb (%) P-valuec
Within 30 days after vaccination 1 3796 1195 (31.5) 1908 363 (19.0) <0.001
Excluding reactogenicity eventsd 581 (15.3) 238 (12.5) 0.004
Within 30 days after vaccination 2 3529 719 (20.4) 1806 223 (12.4) <0.001
Excluding reactogenicity eventsd 362 (10.3) 183 (10.1) 0.924
Within 30 days after vaccination 3 3313 497 (15.0) 1710 184 (10.8) <0.001
Excluding reactogenicity eventsd 288 (8.7) 150 (8.8) 0.916
Within 30 days after any vaccination 3796 1633 (43.0) 1908 600 (31.5) <0.001
Excluding reactogenicity eventsd 998 (26.3) 468 (24.5) 0.158
During the vaccination phase 3796 1939 (51.1) 1908 811 (42.5) <0.001
Excluding reactogenicity eventsd 1436 (37.8) 711 (37.3) 0.685
HAV, hepatitis A virus vaccine; SD, standard deviation.
a N = number of subjects who are in safety population for the speciﬁed analysis interval. The values in this column are used as the denominators for percentages.
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Table 5
Subjects reporting ≥1 reactogenicity event for each analysis interval.
Bivalent rLP2086 HAV/saline
Na nb (%) Na nb (%) P-valuec
Within 7 days after vaccination 1
Any 3796 832 (21.9) 1908 165 (8.7) <0.001
Severe 3796 16 (0.42) 1908 0 0.002
Related 3796 806 (21.2) 1908 157 (8.2) <0.001
Within 7 days after vaccination 2
Any 3529 455 (12.9) 1806 55 (3.1) <0.001
Severe 3529 3 (0.9) 1806 0 0.556
Related 3529 436 (12.4) 1806 50 (2.8) <0.001
Within 7 days after vaccination 3
Any 3313 265 (8.0) 1710 43 (2.5) <0.001
Severe 3313 1 (0.03) 1710 0 >0.999
Related 3313 258 (7.8) 1710 40 (2.3) <0.001
Within 7 days after any vaccination
Any 3796 1057 (27.9) 1908 223 (11.7) <0.001
Severe 3796 20 (0.53) 1908 0 <0.001
Related 3796 1021 (26.9) 1908 207 (10.9) <0.001
During the vaccination phase
Any 3796 1057 (27.9) 1908 223 (11.7) <0.001
Severe 3796 20 (0.53) 1908 0 <0.001
Related 3796 1021 (26.9) 1908 207 (10.9) <0.001
Reactogenicity events were deﬁned as any adverse event with an onset within 7
days  after vaccination and matched a predeﬁned preferred term list.
HAV, hepatitis A virus vaccine.
a N = number of subjects who are in safety population for the speciﬁed analysisn = number of subjects with at least 1 event for the speciﬁed analysis interval.
c Fisher exact test (2-sided) to compare the percentages.
elated to study vaccine remained greater among bivalent rLP2086
ecipients than HAV/saline recipients (7.3% vs 3.0%). This difference
as attributable to a higher proportion of subjects in the biva-
ent rLP2086 group who reported nausea (2.2% vs 1.7%), pain in
xtremity (1.9% vs 1.2%), and injection site warmth (0.4% vs 0%)
uring the vaccination phase, all AEs related to reactogenicity but
ot included in the prespeciﬁed list of terms (Table 1). The propor-
ion of subjects reporting severe AEs during the vaccination phase
n the bivalent rLP2086 and HAV/saline groups, respectively, were
.1% and 0% for nausea and 0.1% and 0.1% for pain in extremity.
here were no reports of injection site warmth in either group that
ere considered severe.
Reactogenicity events during the vaccination phase were more
ommon among bivalent rLP2086 recipients compared with
AV/saline recipients (27.9% vs 11.7%, respectively; Table 5), most
eing mild or moderate in severity. Most severe reactogenicity
vents resolved in <7 days. Immediate AEs were reported by a
imilar proportion of subjects in both groups after vaccination 1
bivalent rLP2086, 1.1%; HAV/saline, 0.8%) and vaccination 3 (biva-
ent rLP2086, 0.5%; HAV/saline, 0.4%). Immediate AEs were more
ommon among bivalent rLP2086 recipients (0.5% vs 0.1%) after
accination 2, when saline was administered to subjects in the
AV/saline group. The most common immediate AEs in the biva-
ent rLP2086 and HAV/saline groups were injection site pain (1.2%
nd 0.8% of subjects, respectively) and syncope (0.1% of subjects in
oth groups). Overall, most immediate reactions were mild.
A similar proportion of subjects in both vaccine groups reported
ays missed from school or work because of an AE during the
accination phase (bivalent rLP2086, 16.8%; HAV/saline, 15.9%). Of
interval. The values in this column are used as the denominators for percentages.
b n = number of subjects with at least 1 event for the speciﬁed analysis interval.
c Fisher exact test (2-sided) to compare the percentages.
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ubjects who reported missing days of school or work, a median of
 days were missed in each vaccine group.
. Discussion
The safety data presented in this study are consistent with that
een in earlier studies of bivalent rLP2086 [14,16,17] that supported
ccelerated approval under breakthrough therapy regulations in
he United States. This large study size facilitates the ability to dis-
ern differences between those who received bivalent rLP2086 and
hose who received control vaccine (or placebo). No new safety
oncerns regarding administration of bivalent rLP2086 in ado-
escents and young adults were identiﬁed. No immunogenicity
ndpoints were assessed in this study, however, previous stud-
es have demonstrated the immunogenicity of bivalent rLP2086 in
hildren [14,19], adolescents [17], and adults [16,18].
Rates of SAEs reported throughout the study were similar in
oth vaccine groups; SAEs related to study vaccine were rare.
o difference in MAEs was observed between groups after any
accination, each vaccination, or throughout the study. Although
he proportion of subjects reporting ≥1 AE was greater after vac-
ination with bivalent rLP2086, the difference was  attributable to
eactogenicity events. When reactogenicity events were excluded,
here was no difference in AEs between groups. E-diaries were not
sed to record reactogenicity events, but study investigators could
eport them as AEs. Reactogenicity events were mostly mild or
oderate and consistent with the reactogenicity proﬁle reported
n earlier studies in which e-diaries were used [14,16,17,19,30,31].
eactogenicity did not affect subjects’ ability to complete the vac-
ination phase and had little effect on the ability to attend school or
ork. Immediate AEs were greater in the bivalent rLP2086 group
fter dose 2, likely because the control group received saline at
his injection. Few subjects discontinued as a result of AEs. Sim-
lar proportions of subjects in both groups completed the full
accination schedule, indicating that the proportion of subjects
eporting AEs was not clinically meaningful and supporting the
onclusion that bivalent rLP2086 was well tolerated. The pro-
ortions of subjects administered bivalent rLP2086 who reported
AEs and who reported MAEs were similar after vaccinations 2
nd 3 compared with after vaccination 1, indicating that poten-
iation did not occur with repeated vaccination. Other studies
n which bivalent rLP2086 was administered with recommended
dolescent vaccines (dTaP/IPV [diphtheria, tetanus, pertussis (acel-
ular, component) and poliomyelitis (inactivated) vaccine] [32] and
uadrivalent human papillomavirus vaccine [HPV4]) found that
oadministration was well tolerated [33].
This was the largest randomized, controlled study designed
o assess the safety, particularly the occurrence of less common
vents, of a recombinant MnB  vaccine conducted to date. An addi-
ional strength of the study was the frequency with which subjects
ere assessed for safety signals, including monthly phone calls
etween vaccination visits and at a month 12 follow-up. A potential
imitation of this study was that, unlike earlier studies of bivalent
LP2086 [14,16,17,19,30,31], e-diaries were not used to capture
elf-reported local and systemic events as this study aimed to iden-
ify less common events. Thus, reactogenicity events in this study
ere reported using the same method as non-reactogenicity events
nd differently from other studies of bivalent rLP2086. Reactogeni-
ity events matching a prespeciﬁed terms list were noted before
nblinding the study data, but not every potential reactogenity
vent was included in that list. The difference in investigator-
eported AEs during the vaccination phase that remained between
he bivalent rLP2086 group and the HAV/saline group after exclu-
ion of prespeciﬁed reactogenicity events were attributable to a
igher proportion of bivalent rLP2086 recipients who  reported
[34 (2016) 1465–1471
nausea, pain in extremity, and injection site warmth. All but 3
of these events occurred within 3 days of vaccination. While not
prespeciﬁed as a reactogenicity event even in this study, nausea
has been a commonly reported reactogenicity AE in studies of
other vaccines [34], but was only reported by 2.2% of subjects who
received bivalent rLP2086 during the vaccination phase here. In
addition, injection site warmth and pain in the extremity in close
proximity to vaccination site are considered reactogenicity events.
Few of these AEs were severe in this study.
5. Conclusions
The results presented provide additional data demonstrating
that bivalent rLP2086 has an acceptable safety and tolerability pro-
ﬁle in healthy individuals ≥10–26 years of age. No new safety
concerns were identiﬁed in this trial of a vaccine that is important
for the prevention of a severe disease.
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